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Abstract
Autophagy delivers cytoplasmic constituents for lysosomal degradation, and thereby facilitates pathogen
degradation and pathogen fragment loading onto MHC molecules for antigen presentation to T cells.
Herpesviruses have been used to demonstrate these novel functions of autophagy, which previously has been
primarily appreciated for its pro-survival role during starvation. In this review, we summarize recent findings how
macroautophagy restricts herpesvirus infections directly, how macroautophagy and chaperone mediated
autophagy contribute to herpesviral antigen presentation on MHC molecules, and which mechanisms
herpesviruses have developed to interfere with these pathways. These studies suggest that herpesviruses
significantly modulate autophagy to escape from its functions in innate and adaptive immunity.
Introduction
Mammalian cells use primarily two proteolytic systems to
catabolise intra- and extracellular material for energy and
macromolecular building block generation. These are
proteasomes and lysosomes. While proteasomes degrade
soluble ubiquitinated proteins, lysosomes destroy ubiqui-
tinated protein aggregates and cell organelles. Interest-
ingly, these degradation mechanisms can also be used to
eliminate pathogens and process their fragments for pre-
sentation to the immune system [1]. Access of substrates
to these proteolytic, and in t h ec a s eo fl y s o s o m e sg e n e r -
ally hydrolytic, machineries is tightly regulated by the
19 s cap complex for the proteasome, and endocytosis,
vesicular sorting and autophagy for lysosomes.
In this context, autophagy delivers cytoplasmic constitu-
ents into lysosomes. Three autophagic pathways have
been identified [2]. The first pathway, microautophagy, is a
process in which substrates bud into the lysosomal lumen
for degradation, but has thus far not been described in
higher eukaryotes. The second pathway, chaperone
mediated autophagy (CMA), transports proteins that con-
tain a KFERQ like recognition sequence across the
lysosomal membrane sequence into the lysosomal lumen.
This transport is assisted by cytosolic and lysosomal cha-
perones as well as LAMP2a. The third pathway, macroau-
tophagy, is currently the best characterised of the three.
Macroautophagy employs 34 gene products, so called
autophagy related (Atg) proteins, to construct a vesicle,
the autophagosome, around its substrate and deliver it for
fusion with lysosomes [3]. Autophagosomes are assembled
from membranes of the rough endoplasmic reticulum,
Golgi apparatus, outer nuclear or mitochondrial mem-
brane, and the cell membrane [4-11]. Autophagosome
assembly nucleates around type III phosphatidylinositol
(PI) 3 kinase complexes, containing the PI3 kinase
hVps34, hVps15, Atg14L and Atg6/Beclin-1 (Figure 1).
Elongation of the autophagosome membrane to an isola-
tion membrane is then achieved with the support of two
ubiquitin-like systems. In one, Atg12 is activated by the
E1-like enzyme Atg7 and then conjugated to Atg5 by the
E2-like enzyme Atg10. The resulting conjugate then
assembles with Atg16L1 and associates with the isolation
membrane to function as an E3-like ligase for the other
ubiquitin-like molecule Atg8 [12,13]. In the Atg8 ubiqui-
tin-like conjugation system, Atg8 is first proteolytically
processed by Atg4 to remove the five C-terminal amino
acids and expose a C-terminal glycine residue for ligation.
Then Atg8 is activated by the E1-like enzyme Atg7
and transferred to the E2-like conjugating enzyme Atg3. It
gets finally linked to phosphatidylethanolamine in the iso-
lation membrane to mediate extension of the forming
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homologue of Atg8, LC3, has been shown to anchor
autophagosome cargo recruitment via p62/SQSTM1,
NBR1 and NDP52 [16-19]. Isolation membrane extension
leads eventually to the completion of the double-
membrane surrounded autophagosome, from whose outer
membrane the Atg12 complex with Atg5 and Atg16L1, as
well as Atg8 are recycled. Atg8, however, remains attached
to the inner autophagosome membrane, and is degraded
with the vesicle cargo. Completed autophagosomes can
then fuse with late endosomes/multivesicular bodies
(MVBs) or lysosomes. These fusion events are also sup-
ported or inhibited by PI3 kinase complexes containing
Atg6/Beclin-1 and UVRAG or Rubicon instead of Atg14,
respectively [20-22]. Fusion with lysosomes requires Rab7
and LAMP2 [23,24], while fusion with MVBs needs Rab11
[25]. In these compartments autophagosome cargo is then
degraded by lysosomal hydrolases.
Of the three autophagy pathways, herpesvirus infec-
tion and their immune control have been shown to be
regulated by macroautophagy. Therefore, we will con-
centrate in this review primarily on the influence of
macroautophagy on herpesvirus infection in vivo, on
T cell responses to herpesviruses and on immune escape
mechanisms of herpesviruses that target this pathway.
Restriction of herpesvirus infection by macroautophagy
in vivo
Regulation of herpesvirus infection by macroautophagy in
vivo has primarily been investigated for herpes simplex
virus type 1 (HSV-1), an a-herpesvirus that causes a vari-
ety of clinical syndromes ranging from mild mucocuta-
neous disease to life-threatening viral encephalitis. In part,
direct pathogen degradation by macroautophagy, termed
“xenophagy”, might be involved in this regulation. Early
on it was recognized that HSV induces macroautophagy
via double-stranded RNA-dependent protein kinase R
(PKR), probably after recognizing convergently transcribed
double-stranded RNA [26] and through activation of
eukaryotic initiation factor (eIF) 2a [27]. While this is
probably not the only pathway by which viruses stimulate
macroautophagy [28,29], in vivo evidence of the impor-
tance of PKR in the restriction of HSV infection in the
central nervous system has been provided [30]. Moreover,
HSV encodes infected cell protein 34.5 (ICP34.5), an
important neurovirulence factor that plays a critical role in
the development of fatal encephalitis in both mice and
humans [31]. ICP34.5 can counteract PKR mediated HSV
restriction and part of its function is blocking macroauto-
phagy [32]. Indeed, recombinant HSV lacking only the
macroautophagy inhibiting domain of ICP34.5 is less neu-
rovirulent in mice [33]. HSV that cannot inhibit macroau-
tophagy replicates to lower viral titers and causes less
pathology. Again this restriction of ICP34.5 mutant HSV
is PKR dependent and does not occur in PKR deficient
mice. These data indicate that during cerebral HSV infec-
tion macroautophagy would control pathology and viral
titers, should the virus not be able to block macroauto-
phagy by its ICP34.5 protein. In addition to this interplay
between HSV and macroautophagy during infection of the
Central Nervous System (CNS), macroautophagy also
affects vaginal HSV infection in mice. Deficiency of
macroautophagy in dendritic cells (DCs) due to excision
of Atg5 leads to elevated pathology and morbidity of intra-
vaginally infected mice [34]. In combination, these data
point towards roles for macroautophagy in the immune
control of HSV in neurones as well as a wider systemic
role in the priming of immune responses by DCs following
intravaginal infection.
Apart from HSV, some in vivo data also exist for a role
of macroautophagy inhibition in the growth of Kaposi sar-
coma associated herpesvirus (KSHV) infected primary
effusion lymphoma (PEL) cells in NOD/SCID mice. KSHV
encoded vFLIP, a homolog of cellular FLICE-like inhibitor
protein (cFLIP), blocks macroautophagy [35]. However,
this inhibition can be compromised by dominant negative
fragments of vFLIP, and these even attenuate PEL growth
in vivo. Thus, KSHV seems to regulate macroautophagy to
promote latently infected B cell growth in vivo.
Herpesvirus antigen processing for MHC presentation by
macroautophagy
As described above, macroautophagy clearly plays an
important role in the control of herpesvirus infection in
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Figure 1 Immune escape from innate restriction and viral
antigen presentation of herpesviruses by macroautophagy.
a-, b- and g-herpesviruses (herpes simplex virus [HSV], human
cytomegalovirus [HCMV], Kaposi sarcoma associated herpesvirus
[KSHV], herpesvirus saimiri [HVS] and murine herpesvirus 68 [MHV-
68]) inhibit macroautophagy by targeting either Atg6/Beclin-1 to
prevent formation of the PI3 kinase complex, marking membranes
with PI3 for the assembly of the autophagosome forming
machinery, or Atg3, which mediates conjugation of the ubiquitin-
like molecule Atg8/LC3, involved in autophagosomal membrane
elongation and substrate recruitment. Incompleteness of these
inhibitory mechanisms allows for viral particle degradation via
lysosomal hydrolysis and antigen presentation on MHC class II
molecules to CD4
+ T cells.
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addition to just innately degrading pathogens. Along
these lines, macroautophagy has now been shown to
influence the adaptive immune response towards herpes-
viruses. By delivering portions of cytoplasm to lysosomes,
macroautophagy provides a route for endogenous pro-
teins to intersect vesicles that form an important part of
the MHC class II processing pathway. These proteins are
then degraded to generate peptide epitopes which, upon
binding into the groove of trafficking MHC class II mole-
cules, are transported to the cell surface for presentation
to CD4
+ T cells.
Formal demonstration that MHC class II peptide epi-
topes can be generated by macroautophagy came from
studies in murine cells on the antigen processing of the
mouse complement C5 protein [36]. The subsequent
observation that an MHC class II epitope was processed
from a bacterial protein by macroautophagy then clearly
showed this pathway was not limited to self-proteins
[37]. The first report of an MHC class II epitope being
processed from a viral protein by macroautophagy came
from studies on a herpesvirus protein. The g-herpesvirus
Epstein Barr virus (EBV) establishes life-long latent infec-
tion in MHC class II positive B cells which is maintained
by its genome maintenance protein, EBV Nuclear Anti-
gen 1 (EBNA1). Following inhibition of macroautophagy
the recognition by EBNA1-specific CD4
+ T cells of EBV-
transformed B Lymphoblastoid Cell Lines (LCLs), which
naturally express physiological levels of EBNA1, was
reduced [38]. Interestingly, further work has since shown
that ablating EBNA1’s nuclear localization sequence
(NLS), causing the protein to be present not just in the
nucleus but also in the cytoplasm, increases the genera-
tion of CD4
+ T cell epitopes from EBNA1 by macroauto-
phagy [39]. Restoration of nuclear localization, by the
insertion of a heterologous NLS, decreased CD4
+ Tc e l l
recognition demonstrating that it was indeed sub-cellular
localization responsible for this effect. EBNA1, by virtue
of its natural localization within the nucleus, enjoys a
measure of protection from macroautophagy mediated
degradation. Whether other viral nuclear antigens behave
similarly remains to be determined.
The studies described above clearly show that macro-
autophagy is important in the processing of antigens
in vitro. What then is the relevance of macroautophagy
to the adaptive immune response in vivo?M i c et h a t
have had the essential macroautophagy gene atg5 condi-
tionally deleted in their DCs, were less efficient at pro-
cessing and presenting MHC class II epitopes from
endogenous and exogenous antigens leading to impaired
Th1 responses, while cross-presentation of exogenous
antigens to CD8
+ T cells was unaffected [34]. This study
clearly demonstrates that macroautophagy plays an
important role in the ability of DCs to process and
present antigens to CD4
+ T cells. However, the normal
state of affairs is that viruses infect hosts that have an
intact macroautophagy pathway in their immune cells.
Given the importance of macroautophagy for the correct
functioning of DCs (and therefore adaptive immunity as
a whole) it would seem an obvious pathway to be tar-
geted by viruses seeking to subvert immunity. Herpes-
viruses have evolved a variety of mechanisms to evade
host immune responses and targeting autophagy can
now be added to their repertoire. HSV-1 expressed
ICP34.5 inhibits macroautophagy by binding the cellular
protein Atg6/Beclin-1 [33]. Removal of the Beclin-1
binding domain from ICP34.5 did not affect HSV-1
replication in vitro, nor its neurovirulence in Rag1
-/-
mice that lack B and T cells [40]. However, neuroviru-
lence was reduced in immunocompetent mice, a result
suggesting that by binding Atg6/Beclin-1 and inhibiting
macroautophagy, ICP34.5 interferes with the adaptive
immune response to HSV. This was shown to be the
case, with mice infected with the mutant virus (unable
to inhibit macroautophagy) making much larger HSV-1
specific CD4
+ T cell responses relative to mice infected
with a control virus [40]. These studies suggest that
macroautophagy enhances CD4
+ Tc e l li m m u n i t yi n
vivo by assisting viral ant i g e np r e s e n t a t i o no nM H C
class II molecules.
Another study using HSV has revealed that macroau-
tophagy may be important for CD8
+ Tc e l li m m u n i t ya s
well. In murine macrophages infected with HSV-1, an
MHC class I epitope from the gB protein was processed
by the classic proteasomal pathway of antigen presenta-
tion during the early stages of infection, but by a vacuo-
lar pathway at later stages [8]. As expected for HSV-1,
macroautophagy was inhibited during the early stages of
infection. However, at later stages the cells contained
not only conventional autophagosomes in the cytoplasm,
but also four-layered membrane structures connected to
the nucleus; both were positive for LC3, a standard mar-
ker of autophagosomes. These unusual multi-membrane
autophagosome structures were, like conventional
autophagosomes, comprised of membranes from the
endoplasmic reticulum and nucleus. The fact that these
novel autophagosome structures were not seen in
macrophages treated with drugs or stress to induce
autophagy raises the possibility that this is a response to
virus infection. Interestingly, only conventional autopha-
gosomes were observed in cells infected with an HSV-1
mutant that, through deletion of the ICP34.5 gene, was
unable to interfere with conventional macroautophagy.
One possibility is that this unusual nuclear macroauto-
phagy is a cellular response to a combination of HSV
infection and macroautophagy blockade.
All the work described above has focused on macroauto-
phagy as the mechanism of processing and presentation of
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text other autophagy pathways could also potentially contri-
bute. CMA has been less well studied, but this pathway has
also been shown to be capable of generating CD4
+ T cell
epitopes from cellular proteins [41]. What about viral pro-
teins in infected cells? Unlike macroautophagy, which is
generally considered to be sequence unspecific, proteins
degraded by CMA require a pentapeptide motif (KFERQ or
a biochemically related sequence). Although this may at
first seem to compromise CMA’s value as an antigen pro-
cessing pathway, it is important to note that KFERQ-like
motifs occur frequently in proteins; for example, almost
30% of cellular proteins contain such a motif [42]. The
chances that viruses lack a suitable motif in any of their
proteins seem remote and it is likely only to be a matter of
time before a virus epitope is shown to be generated by
CMA. It will be interesting to see if any of the herpesviruses
encode proteins that are substrates of CMA and, if so,
whether they have also evolved countermeasures to this
processing pathway.
Therefore, intracellular antigen processing for MHC
class II presentation via autophagy has now been docu-
mented for macroautophagy and CMA. It, however,
remains to be explored how autophagy can contribute
to extracellular antigen processing and antigen packa-
ging for cross-presentation [43].
Immune escape from autophagy by herpesviruses
Autophagy has recently been identified as an important
intracellular effector mechanism of host immunity. By
delivering intracellular bacteria and viruses to lysosomes
for destruction via “xenophagy”, and by importing viral
nucleic acids to immune sensors in the endo/lysosomal
compartment, macroautophagy plays a critical role in
the defense against a number of chronic intracellular
pathogens [1,2,44]. To ensure their own replication and
to enhance their life cycle, ma n ym i c r o b e sh a v ed e v e l -
oped countermeasures and escape mechanisms to evade,
subvert, or exploit macroautophagy, thereby adding to
the cat-and-mouse game of microbial pathogenesis and
host-pathogen interactions.
Given the intimate virus-host relationship required to
establish a latent state of lifetime persistence in the
infected host, it is not surprising that herpesviruses
belong to the continuously growing list of viruses that
have developed strategies to defeat the antiviral effects of
macroautophagy [45-47]. In fact, representatives of all
three herpesvirus subfamilies encode proteins or induce
cellular signaling pathways that affect macroautophagy.
The best studied example is HSV-1 [48]. A major break-
through in understanding HSV-1 neurovirulence was the
identification of ICP34.5 as an important neurovirulence
factor that suppresses macroautophagy in infected cells
via two different pathways: the dephosphorylation of
translation initiation factor eIF2a and the binding to the
macroautophagy-promoting protein Atg6/Beclin-1 [27,33].
The double-stranded RNA-dependent kinase PKR stimu-
lates macroautophagy induction through eIF2a phosphor-
ylation and ICP34.5 is able to antagonize this response by
recruiting the host phosphatase PP1a to dephosphorylate
eIF2a. In addition, ICP34.5 can also bind to Atg6/Beclin-1
and might prevent it from entering the PI3 kinase complex
to induce macroautophagy [49]. While the precise
mechanisms by which macroautophagy protects against
viral neuropathology are still unclear, it seems likely that
macroautophagy functions to restrict viral replication. In
ultrastructural studies, virions of the ICP34.5 deletion
mutant have been detected within autophagosomes
[31,50]. Moreover, metabolic labeling of viral proteins
demonstrated increased rates of degradation in the
ICP34.5 deletion mutant virus-infected cells compared
with wild-type HSV-1 virus-infected cells [50]. These
results indicate that virion targeting for xenophagic degra-
dation is compromised by ICP34.5 [33].
Interestingly, other viruses that cause CNS disease also
appear to suppress host macroautophagy. Human cyto-
megalovirus (HCMV), which belongs to the b-herpes-
virus family and which causes severe CNS infections in
neonates and immunocompromised adults, inhibits host
macroautophagy, albeit with mechanisms different from
those of HSV-1 [51]. In primary human fibroblasts,
HCMV can block macroautophagy by activating the
mTOR signaling pathway [52], which is known to sup-
press macroautophagy. Moreover, lithium chloride-
induced macroautophagy, which is mTOR-independent,
is also suppressed by HCMV infection [53]. Thus,
HCMV is able to inhibit macroautophagy via both
mTOR-dependent and -independent pathways [51].
It is worth noting that in addition to these neurotropic
viruses, other viruses, such as the oncogenic g-herpes-
viruses that infect extraneural tissues, also encode inhibi-
tors of Atg6/Beclin-1 and macroautophagy. Although the
role of macroautophagy in g-herpesvirus pathogenesis is
not yet clear, these observations suggest that viral evasion
of macroautophagy is probably not restricted to viruses
that specifically infect the CNS. All members of the
g-herpesvirus family have in common that they express
orthologs of Bcl-2, the cellular prototype inhibitor of
apoptosis. These include orf16 of KSHV, herpesvirus sai-
miri and rhesus rhadinovirus, the BHRF1 and BALF-1
proteins of EBV, and the M11 protein of MHV68 [54]. In
this context it is important to mention that apoptosis and
macroautophagy are tightly interconnected and coordi-
nately regulated. Besides preventing apoptosis, Bcl-2 also
inhibits stress-induced macroautophagic cell death by
binding to Atg6/Beclin-1 [55]. Several of the viral homo-
logues of Bcl-2 have been shown to bind to Atg6/Beclin-
1 and to prevent it from binding to PI3 kinase complexes
Taylor et al. Herpesviridae 2011, 2:2
http://www.herpesviridae.org/content/2/1/2
Page 4 of 7and, hence, suppress the initiation of macroautophagy
[22,56,57]. Thus, vBcl-2 s of g-herpesviruses potentially
inhibit both apoptosis and macroautophagy by binding to
specific effectors of these pathways. This propensity of
the g-herpesvirus vBcl-2 proteins implies that macroauto-
phagy might at least in part impact on viral persistence.
Of note, it has recently been reported that maintenance
of persistent MHV68 infection is impaired in a mutant
virus lacking the anti-macroautophagic activity of vBcl-2
compared to the wild-type virus [56], suggesting that
MHV68, via vBcl-2, evades macroautophagy-mediated
antiviral responses.
Besides targeting Atg6/Beclin-1, several herpesviruses
including KSHV and herpesvirus saimiri can also sup-
press macroautophagy by expressing vFLIP, a homolog
of cFLIP [29]. vFLIP, similarly to cFLIP, can bind to
and prevent Atg3 from binding and processing LC3.
This enzymatic activity of Atg3 is critical for the lipida-
tion of Atg8/LC3 and the formation of autophagic
vacuoles [58].
As mentioned above, EBV codes for two vBcl2 pro-
teins (BALF1 and BHRF1) that are both expressed early
during the lytic cycle, implying a protective role of these
gene products during viral replication. In addition, both
proteins are expressed early after infection of primary B
cells [59], and BHRF1 also during the latent phase of
infection [60]. Although it is currently not known
whether these two proteins bind to Atg6/Beclin-1, these
findings might indicate that EBV modulates macroauto-
phagy at least during two phases of its life cycle.
Studies in other viral systems have demonstrated that
virus replication, biogenesis, and egress can benefit from
an increase in macroautophagy activity [61], and several
herpesviruses including EBV, KSHV and varicella-zoster
virus (VZV) have recently been demonstrated to not
just suppress, but also induce macroautophagy. How
VZV induces macroautophagy is unclear, but it does not
seem to require late gene products, since the suppres-
sion of viral late gene expression with phosphonoacetic
acid does not abolish VZV-induced macroautophagy
[62]. The EBV latent membrane protein 1 (LMP-1) can
induce macroautophagy in a dose-dependent manner
[63]. Interestingly, the expression level of EBV LMP-1
also seems to be regulated by macroautophagy, as its
level increases if macroautophagy is suppressed by short
hairpin RNA (shRNA) targeting Atg6/Beclin-1 or Atg7
[29,63]. Furthermore, RTA, an essential viral protein for
KSHV lytic reactivation, enhances macroautophagy and
thereby facilitates lytic replication [64].
Thus, herpesviruses can affect macroautophagy either
positively or negatively, depending on the virus, the
virus’ life cycle, and potentially the cellular context.
However, with the exception of HSV-1, which sup-
presses macroautophagy to enhance its replication and
pathogenesis, the role of macroautophagy in the life
cycle of other herpesviruses still needs to be further
elucidated.
Conclusions
Herpesviruses as one of the most successful families of
pathogens have developed mechanisms to inhibit both
innate and adaptive immune responses that rely on
macroautophagy, and require this regulation for patho-
genicity in vivo. These immune escape mechanisms of
herpesviruses might, however, also affect functions that
macroautophagy has beyond resistance to pathogens.
Along these lines they could interfere with clearance of
protein aggregates by macroautophagy during CNS
infection [65,66], compromise the role of macroauto-
phagy in maintaining genome integrity as a protective
mechanism against tumors [67] and impair protective
mechanisms of macroautophagy against aging [68].
Thus, the pathomechanisms of chronic herpesvirus
infections could potentially extend beyond direct trans-
formation of cells, tissue destruction and immuno-
pathology after lytic reactivation. As the list of
h e r p e s v i r u sa s s o c i a t e dd i s e a s e si nh u m a n sg r o w s ,t h e
potential for novel mechanisms of pathogenesis invol-
ving autophagy should be borne in mind.
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